abstract |
The present invention relates to quinoline and quinoxaline compounds that inhibit the activity of platelet-derived growth factor and / or tyrosine kinase p56 tyrosine kinase, pharmaceutical compositions containing these compounds, and the use of these compounds for treating a patient suffering from (or susceptible) disorders and conditions including cell differentiation, proliferation, production of extracellular matrix or mediator release, and / or T cell activation and proliferation. |